[go: up one dir, main page]

AU2002339683A1 - Agonist and antagonists of redax for the treatment of metabolic disorders - Google Patents

Agonist and antagonists of redax for the treatment of metabolic disorders

Info

Publication number
AU2002339683A1
AU2002339683A1 AU2002339683A AU2002339683A AU2002339683A1 AU 2002339683 A1 AU2002339683 A1 AU 2002339683A1 AU 2002339683 A AU2002339683 A AU 2002339683A AU 2002339683 A AU2002339683 A AU 2002339683A AU 2002339683 A1 AU2002339683 A1 AU 2002339683A1
Authority
AU
Australia
Prior art keywords
redax
agonist
antagonists
treatment
metabolic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339683A
Inventor
Kristen Briggs
Deno Dialynas
John Lucas
Aaron Scalia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Publication of AU2002339683A1 publication Critical patent/AU2002339683A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002339683A 2001-12-05 2002-10-14 Agonist and antagonists of redax for the treatment of metabolic disorders Abandoned AU2002339683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33835601P 2001-12-05 2001-12-05
US60/338,356 2001-12-05
PCT/IB2002/004626 WO2003047614A1 (en) 2001-12-05 2002-10-14 Agonist and antagonists of redax for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
AU2002339683A1 true AU2002339683A1 (en) 2003-06-17

Family

ID=23324493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339683A Abandoned AU2002339683A1 (en) 2001-12-05 2002-10-14 Agonist and antagonists of redax for the treatment of metabolic disorders

Country Status (2)

Country Link
AU (1) AU2002339683A1 (en)
WO (1) WO2003047614A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021577A1 (en) * 1997-10-29 1999-05-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibiting smooth muscle proliferation, method for the diagnosis of arteriosclerosis, and kits therefor
EP1085897A4 (en) * 1998-05-21 2003-03-12 Smithkline Beecham Corp Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein)
EP1177296A2 (en) * 1999-05-11 2002-02-06 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
CA2374387A1 (en) * 1999-05-27 2000-12-07 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp7
WO2001005834A1 (en) * 1999-07-16 2001-01-25 Human Genome Sciences, Inc. Human tumor necrosis factor receptors tr13 and tr14
DE60135439D1 (en) * 2000-01-14 2008-10-02 Serono Genetics Inst Sa OBG3 GLOBULAR HEAD AND ITS USES FOR REDUCING BODY WEIGHT

Also Published As

Publication number Publication date
WO2003047614A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
AU2002339691A1 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002339683A1 (en) Agonist and antagonists of redax for the treatment of metabolic disorders
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2003259759A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
AU2002339685A1 (en) Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002313580A1 (en) Xobesin agonists and antagonists for the treatment of metabolic disorders
AU2002321761A1 (en) Agonists and antagonists of disomet for the treatment of metabolic disorders
AU2002321766A1 (en) Agonists and antagonists of obesingen for the treatment of metabolic disorders
AU2002321769A1 (en) Agonists and antagonists of cobesin for the treatment of metabolic disorders
AU2002321770A1 (en) Agonists and antagonists of genceptin for the treatment of metabolic disorders
AU2002324297A1 (en) Agonists and antagonists of moxifin for the treatment of metabolic disorders
AU2002324300A1 (en) Agonists and antagonists of moceptin for the treatment of metabolic disorders
AU2002329001A1 (en) Agonists and antagonists of cylixin for the treatment of metabolic disorders
AU2002339681A1 (en) Agonists and antagonists of glucomin for the treatment of metabolic disorders
AU2002321767A1 (en) Tr xidatin agonists and antagonists treatment of metabolic disorders
AU2002339668A1 (en) Treatment of metabolic disorders with xitar agonists and antagonists
AU2002328096A1 (en) Faxigen agonists and antagonists in the treatment of metabolic disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase